One way to treat cancer is to inhibit the development of the blood vessels that cancers need to grow and spread (a process called angiogenesis). Aflibercept and REGN910 are both “anti-angiogenesis” drugs. Aflibercept works by targeting a protein involved in angiogenesis called VEGF. REGN910 targets another angiogenesis protein, called Ang2.
Aflibercept is already approved for treating advanced colorectal cancer and, as an injection, for an eye disease; its use in ovarian cancer is considered investigational. REGN910 is also investigational. In this study, researchers want to find the highest doses of aflibercept and REGN910 that can be given safely in combination with paclitaxel in women with ovarian cancer that has come back within six months of treatment with carboplatin or cisplatin.